Bio Medica Laboratories IPO GMP: Price Band, Lot Size, Allotment & Listing Date

The Bio Medica Laboratories IPO GMP is attracting attention among SME IPO investors as the healthcare and pharmaceutical sector continues to witness growing interest in the stock market. Investors are closely monitoring the Grey Market Premium (GMP), subscription demand, and listing expectations ahead of the IPO launch and allotment process.

Bio Medica Laboratories IPO is a book-built issue worth ₹52.43 crores. The IPO comprises a combination of a fresh issue of 0.34 crore shares aggregating to ₹47.19 crores and an offer for sale (OFS) of 0.04 crore shares amounting to ₹5.24 crores. The fresh issue proceeds are expected to support business expansion and operational requirements, while the OFS allows existing shareholders to partially dilute their holdings.

The IPO subscription window opened on May 21, 2026, and will remain open until May 25, 2026. Investors can apply for the IPO through registered brokerage platforms and supported banking channels during the subscription period.

As per the tentative IPO schedule, the basis of allotment for the Bio Medica Laboratories IPO is expected to be finalized on May 26, 2026. The company is likely to be listed on the NSE SME platform with a tentative listing date of May 29, 2026.

Bio Medica Laboratories IPO has fixed a price band of ₹132 to ₹139 per share. Investors can place bids within this range depending on their market outlook and investment strategy. The IPO lot size has been set at 1,000 shares per lot, making it suitable primarily for investors comfortable with SME IPO investments.

For retail investors, the minimum investment requirement is approximately ₹2,78,000 for 2 lots or 2,000 shares at the upper price band. Meanwhile, High Net-Worth Individuals (HNIs) need to apply for a minimum of 3 lots, equivalent to 3,000 shares, requiring an investment of around ₹4,17,000.

The Bio Medica Laboratories IPO GMP is expected to remain an important indicator of investor sentiment before listing day. Grey Market Premium reflects the unofficial premium at which IPO shares trade in the unlisted market and is often used to estimate possible listing gains. However, GMP is unofficial and can fluctuate rapidly based on overall market conditions and subscription demand.

Investors should evaluate factors such as financial performance, valuation, industry outlook, competitive position, and growth prospects before applying for the IPO. While SME IPOs can offer strong listing opportunities, they also carry risks associated with lower liquidity and higher market volatility.

As the IPO moves toward allotment and listing, investors will continue tracking the latest Bio Medica Laboratories IPO GMP, subscription figures, and market response for insights into potential listing performance.